SCHEMBL19922862

SCHEMBL19922862

COC(=O)c1ccc(C(Br)CCC(F)(F)C(F)(F)F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
DPP4 P27487 2/20 0.40
NOTUM Q6P988 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
CA12 O43570 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
POLB P06746 1/20 0.38
GAA P10253 2/20 0.38
ALDH1A1 P00352 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
OPRD1 P41143 1/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19922112 0.90 MAPT (0.44) MAPTDPP4NOTUMCA1CA2
SCHEMBL1867683 0.79 SLC6A2 (0.50) MAPTDPP4CA1CA2TDP1
SCHEMBL19922813 0.78 MAPT (0.46) MAPTDPP4CA1CA2TDP1
SCHEMBL25335887 0.76 MAPT (0.50) MAPTDPP4CA1CA2TDP1
SCHEMBL8759187 0.76 MAPT (0.50) MAPTDPP4CA1CA2TDP1
SCHEMBL19922892 0.75 MGLL (0.48) MAPTCA1CA2TDP1CA12
SCHEMBL28261584 0.74 MGLL (0.50) MAPTCA1CA2TDP1CA12
SCHEMBL19922885 0.74 MGLL (0.50) MAPTCA1CA2TDP1CA12
SCHEMBL28676869 0.74 MAPT (0.49) MAPTDPP4CA1CA2TDP1
SCHEMBL19922872 0.74 MAPT (0.42) MAPTTDP1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3510022-B1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2020-08-05 EP disclosed
EP-3510022-A1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS Janssen Pharmaceutica NV (BE) 2019-07-17 EP disclosed
US-10251864-B2 Indole derivatives useful as glucagon receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2019-04-09 US disclosed
US-10251864-B2 Indole derivatives useful as glucagon receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2019-04-09 US disclosed
WO-2018048761-A1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2018-03-15 WO disclosed
US-20180064686-A1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2018-03-08 US disclosed
US-20180064686-A1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2018-03-08 US disclosed
US-20180064686-A1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2018-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10251864-B2 Indole derivatives useful as glucagon receptor antagonists GPR119, GIPR, GLP1R MAPT 4089/4885DPP4 149/4885NOTUM 2857/4885
US-20180064686-A1 INDOLE DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS GPR119, GIPR, GLP1R MAPT 4089/4885DPP4 149/4885NOTUM 2857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.